GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Market Cap

Anixa Biosciences (Anixa Biosciences) Market Cap : $95.38 Mil (As of Apr. 30, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anixa Biosciences's share price for the quarter that ended in Jan. 2024 was $4.54. Anixa Biosciences's Shares Outstanding (EOP) for the quarter that ended in Jan. 2024 was 31.75 Mil. Therefore, Anixa Biosciences's market cap for the quarter that ended in Jan. 2024 was $144.16 Mil.

Anixa Biosciences's quarterly market cap declined from Jul. 2023 ($111.35 Mil) to Oct. 2023 ($98.42 Mil) but then increased from Oct. 2023 ($98.42 Mil) to Jan. 2024 ($144.16 Mil).

Anixa Biosciences's annual market cap increased from Oct. 2021 ($143.34 Mil) to Oct. 2022 ($173.12 Mil) but then declined from Oct. 2022 ($173.12 Mil) to Oct. 2023 ($98.42 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anixa Biosciences's Enterprise Value for Today is $73.12 Mil.


Anixa Biosciences Market Cap Historical Data

The historical data trend for Anixa Biosciences's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Market Cap Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.68 49.95 143.34 173.12 98.42

Anixa Biosciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.13 126.31 111.35 98.42 144.16

Competitive Comparison of Anixa Biosciences's Market Cap

For the Biotechnology subindustry, Anixa Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Market Cap distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Market Cap falls into.



Anixa Biosciences Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Anixa Biosciences's Market Cap for the fiscal year that ended in Oct. 2023 is calculated as

Market Cap (A: Oct. 2023 )=Share Price (A: Oct. 2023 )*Shares Outstanding (EOP) (A: Oct. 2023 )
=$3.16*31.1452
=$98.42

Anixa Biosciences's Market Cap for the quarter that ended in Jan. 2024 is calculated as

Market Cap (Q: Jan. 2024 )=Share Price (Q: Jan. 2024 )*Shares Outstanding (EOP) (Q: Jan. 2024 )
=$4.54*31.7544
=$144.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anixa Biosciences  (NAS:ANIX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Anixa Biosciences Market Cap Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747